Assignee
MYRIAD GENETICS INC
US·115 granted patents·152 pending applications·1,852 citations·filing 1995–2025
Top patents by PatentIndex Score
267 records- 0198US5869242AMass spectrometry to assess DNA sequence polymorphismsMYRIAD GENETICS INC·Filed 1995·Granted Feb 9, 1999·350 cites·12 claims
- 0296US6251610B1Method for sequencing both strands of a double stranded DNA in a single sequencing reactionMYRIAD GENETICS INC·Filed 2000·Granted Jun 26, 2001·153 cites·1 claims
- 0395US12221656B2Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2022·Granted Feb 11, 2025·3 cites·18 claims
- 0495US6562576B2Yeast two-hybrid system and use thereofMYRIAD GENETICS INC·Filed 2002·Granted May 13, 2003·59 cites·28 claims
- 0593US9574229B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2016·Granted Feb 21, 2017·11 cites·41 claims
- 0693US9279156B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2013·Granted Mar 8, 2016·16 cites·18 claims
- 0792US6444419B1TMPRSS2 is a tumor suppressorMYRIAD GENETICS INC·Filed 2000·Granted Sep 3, 2002·32 cites·2 claims
- 0890US10876164B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2015·Granted Dec 29, 2020·5 cites·4 claims
- 0989US11174517B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2016·Granted Nov 16, 2021·4 cites·7 claims
- 1089US9976188B2Cancer biomarkersMYRIAD GENETICS INC·Filed 2017·Granted May 22, 2018·5 cites·8 claims
- 1189US5709999ALinked breast and ovarian cancer susceptibility geneMYRIAD GENETICS INC·Filed 1995·Granted Jan 20, 1998·96 cites·35 claims
- 1288US10954568B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2015·Granted Mar 23, 2021·3 cites·4 claims
- 1388US5710001A17q-linked breast and ovarian cancer susceptibility geneMYRIAD GENETICS INC·Filed 1995·Granted Jan 20, 1998·61 cites·35 claims
- 1488US2024182979A1Cancer biomarkersMYRIAD GENETICS INC·Filed 2024·Application pending·0 cites
- 1587US10626449B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2017·Granted Apr 21, 2020·2 cites·13 claims
- 1686US11505832B2Method of using biomarkers and clinical variables for predicting chemotherapy benefitMYRIAD GENETICS INC·Filed 2020·Granted Nov 22, 2022·2 cites·20 claims
- 1786US10612098B2Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2016·Granted Apr 7, 2020·2 cites·15 claims
- 1886US6410725B1Method for extracting DNA from dried specimensMYRIAD GENETICS INC·Filed 2000·Granted Jun 25, 2002·22 cites·19 claims
- 1985US7410944B1Depression geneMYRIAD GENETICS INC·Filed 2006·Granted Aug 12, 2008·7 cites·12 claims
- 2085US6033857AChromosome 13-linked breast cancer susceptibility geneMYRIAD GENETICS INC·Filed 1998·Granted Mar 7, 2000·48 cites·8 claims
- 2184USD730981SFormMYRIAD GENETICS INC·Filed 2014·Granted Jun 2, 2015·36 cites·1 claims
- 2284US6166194ATMPRSS2 is a tumor suppressorMYRIAD GENETICS INC·Filed 1999·Granted Dec 26, 2000·38 cites·1 claims
- 2384US6087099AMethod for sequencing both strands of a double stranded DNA in a single sequencing reactionMYRIAD GENETICS INC·Filed 1997·Granted Jul 11, 2000·92 cites·6 claims
- 2484US5789206AMethod for ligating adaptors to nucleic acids which methods are useful for obtaining the ends of genesMYRIAD GENETICS INC·Filed 1995·Granted Aug 4, 1998·105 cites·2 claims
- 2584US2026063636A1Signatures for predicting cancer immune therapy responseMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 2683US11225685B2Methods and materials for assessing allelic imbalanceMYRIAD GENETICS INC·Filed 2020·Granted Jan 18, 2022·1 cites·20 claims
- 2783US7250497B2Large deletions in human BRCA1 gene and use thereofMYRIAD GENETICS INC·Filed 2003·Granted Jul 31, 2007·14 cites·20 claims
- 2882US7547804B2Compounds, compositions, and methods employing sameMYRIAD GENETICS INC·Filed 2005·Granted Jun 16, 2009·8 cites·26 claims
- 2982US7008941B2Reverse-turn mimetics and methods relating theretoMYRIAD GENETICS INC·Filed 2002·Granted Mar 7, 2006·11 cites·44 claims
- 3082US6841352B2Mating-based method for detecting protein—protein interactionMYRIAD GENETICS INC·Filed 2002·Granted Jan 11, 2005·12 cites·57 claims
- 3182US6551786B2Screen assay for selecting protein-protein interaction modulatorsMYRIAD GENETICS INC·Filed 2002·Granted Apr 22, 2003·16 cites·26 claims
- 3281US7338775B1Enzyme assay and use thereofMYRIAD GENETICS INC·Filed 2006·Granted Mar 4, 2008·9 cites·7 claims
- 3381US6653102B2Nucleic acid encoding a phosphatase 2C that interacts with Fe 65MYRIAD GENETICS INC·Filed 2001·Granted Nov 25, 2003·16 cites·4 claims
- 3481US2023111438A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 3580US9388472B2Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2014·Granted Jul 12, 2016·3 cites·36 claims
- 3680US6895337B1Method of identifying genomic rearrangementsMYRIAD GENETICS INC·Filed 2002·Granted May 17, 2005·8 cites·33 claims
- 3780US2025250643A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 3879US10519513B2Cancer BiomarkersMYRIAD GENETICS INC·Filed 2019·Granted Dec 31, 2019·1 cites·8 claims
- 3979US7422853B1RNA interference using a universal targetMYRIAD GENETICS INC·Filed 2003·Granted Sep 9, 2008·16 cites·34 claims
- 4079US7335468B2TSG101-GAG interaction and use thereofMYRIAD GENETICS INC·Filed 2003·Granted Feb 26, 2008·8 cites·8 claims
- 4179US5747282A17Q-linked breast and ovarian cancer susceptibility geneMYRIAD GENETICS INC·Filed 1995·Granted May 5, 1998·61 cites·20 claims
- 4279US2023094830A1Signatures for predicting cancer immune therapy responseMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 4378US11174519B2Method of treating cancerMYRIAD GENETICS INC·Filed 2019·Granted Nov 16, 2021·0 cites·11 claims
- 4478US11021752B2Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD GENETICS INC·Filed 2014·Granted Jun 1, 2021·1 cites·10 claims
- 4578US10612099B2Genes and gene signatures for diagnosis and treatment of melanomaMYRIAD GENETICS INC·Filed 2016·Granted Apr 7, 2020·1 cites·5 claims
- 4678US7195873B2Drug response marker in beta-1 adrenergic receptor geneMYRIAD GENETICS INC·Filed 2002·Granted Mar 27, 2007·9 cites·12 claims
- 4778US2022205046A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2021·Application pending·0 cites
- 4878US2022259675A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 4977US5693473ALinked breast and ovarian cancer susceptibility geneMYRIAD GENETICS INC·Filed 1995·Granted Dec 2, 1997·66 cites·14 claims
- 5077US2025215509A1Methods and materials for assessing loss of heterozygosityMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 267 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MYRIAD GENETICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →